Kopran Ltd
Kopran Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Kopran Laboratories operates in a fast-growing Indian diagnostic industry expected to grow at a CAGR of 14% over the next 5 years, reaching $25 billion by FY '28 and nearly tripling by 2034. The diagnostics industry Kopran Labs operates in is growing at a CAGR of 14%-15%.
From Kopran Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Kopran Laboratories operates in a fast-growing Indian diagnostic industry expected to grow at a CAGR of 14% over the next 5 years, reaching $25 billion by FY '28 and nearly tripling by 2034.
- Kopran Labs has shown strong past growth, increasing top line threefold from INR35 crores to INR103 crores in 4 years.
- The diagnostic segment is expected to participate in this industry growth, with new divisions added recently to drive further revenue.
- South region operations, started about 3 years ago, hold significant growth potential.
- Annual addition of 20-25 diagnostic machines is expected, supporting steady volume growth.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Kopran Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Kopran Laboratories has a current capital investment approach involving approximately 120 machines deployed on a contracted basis.
- Annually, they add about 20-25 machines to their reagent rental business.
- For the current year mentioned, 23-24 machines were added, with a possibility of 1-2 more before year-end.
- The expected annual investment in machines is around INR 7 to 8 crores.
- All these capital expenditures are funded through internal accruals, supported by a substantial cash reserve.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Kopran Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Kopran Laboratories has close to 120 machines deployed across India on a contracted basis.
- Each machine is part of a long-term contract averaging around 5 to 5.5 years.
- The company typically adds 20 to 25 new machines annually; 23-24 machines were added in the current year.
- These contracts ensure recurrent purchase of consumables, forming an annuity-like revenue stream.
- Kopran anticipates continuing this orderbook growth annually, funded through internal accruals.
- They maintain warehousing and cold chain logistics to support ongoing orders.
2 more points management made on order book & pipeline
Kopran Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹234 Cr, net profit ₹19 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Kopran Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- SMS Pharmaceuticals Ltd (Q3 FY25)
Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Wockhardt Ltd (Q3 FY25)
725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…
- NGL Fine Chem Ltd (Q3 FY25)
Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8). Key concall takeaways from NGL Fine Chem Ltd's Q3 FY25…
- Shree Ganesh Remedies Ltd (Q3 FY25)
Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key concall takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 earnings call — and how it ranks against sector…
Frequently Asked Questions
What were Kopran Ltd Q3 FY25 results?
Kopran Laboratories operates in a fast-growing Indian diagnostic industry expected to grow at a CAGR of 14% over the next 5 years, reaching $25 billion by FY '28 and nearly tripling by 2034. The diagnostics industry Kopran Labs operates in is growing at a CAGR of 14%-15%.
What is Kopran Ltd share price analysis?
Kopran Ltd currently shows a neutral. The stock trades at a P/E of 37.1 with a market cap of ₹955 Cr. Investors should review the full earnings analysis for detailed insights.
Is Kopran Ltd planning capital expenditure?
Kopran Laboratories has a current capital investment approach involving approximately 120 machines deployed on a contracted basis.
Keep Kopran Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.